Management of Peripartum Cardiomyopathy

Introduction to Guideline-Based Care

The American College of Cardiology recommends that GDMT should be continued indefinitely after ejection fraction recovery in patients with peripartum cardiomyopathy, as discontinuation carries a 40% risk of relapse within 6 months 1, 2
The American Heart Association, American College of Cardiology, and Heart Failure Society of America provide a Class I, Level B-R recommendation that GDMT should be continued in patients with heart failure and improved ejection fraction to prevent relapse of heart failure and left ventricular dysfunction, even in asymptomatic patients 1, 2

A landmark open-label randomized controlled trial demonstrated that phased withdrawal of heart failure medications in patients with previous dilated cardiomyopathy resulted in relapse in 40% of patients within 6 months 1, 2
Treatment was successfully withdrawn in only 50% of patients, with the remainder experiencing significant deterioration 1, 2
Relapse was defined by at least one of: LVEF reduction >10% and to <50%; LVEDV increase >10% above normal range; NT-proBNP doubling to >400 ng/L; or clinical heart failure 1, 2

The American Heart Association states that the duration of standard heart failure medications should be indefinite when left ventricular function fails to normalize in patients with peripartum cardiomyopathy 3
Even when ventricular function normalizes after 12 months of treatment, discontinuation of heart failure medications is very controversial and not supported by trial data 3
Close clinical follow-up with annual assessment of LVEF should be performed for a minimum of several years after recovery, particularly if subsequent pregnancy is being considered 3

The American College of Cardiology recommends that the following medications should be continued indefinitely after EF recovery in PPCM patients: beta-blockers, ACE inhibitors, ARBs, or ARNIs, mineralocorticoid receptor antagonists, SGLT2 inhibitors, and loop diuretics as needed for volume management 1, 2, 3, 4

Annual echocardiographic assessment of LVEF for a minimum of several years after recovery is recommended by the American Heart Association 3
Serial NT-proBNP measurements can help detect early signs of relapse before clinical deterioration 1, 2
Monitor for worsening Kansas City Cardiomyopathy Questionnaire scores, which declined significantly with medication withdrawal in trials 1, 2
Assess for increases in left ventricular volumes and reductions in ejection fraction at each follow-up 1, 2

The American College of Cardiology advises against interpreting symptom resolution and EF normalization as "cure"—this represents remission requiring ongoing treatment, not recovery 1, 2
Do not assume that normalized biomarkers and normalized LVEDV indicate it is safe to discontinue therapy—even these patients had 40% relapse rates 1, 2
Avoid discontinuing GDMT based solely on patient preference to avoid medications, as the risk of relapse with potentially irreversible cardiac dysfunction outweighs medication burden 1, 2
Do not confuse adverse events commonly attributed to GDMT with the actual disease process—adverse events occur at similar rates in placebo and intervention arms of heart failure trials 5

Women with PPCM whose ventricular function does not normalize after pregnancy should be counseled against subsequent pregnancy due to significant morbidity and mortality risk, according to the American Heart Association 3
Cardiac device therapy with ICD, CRT, or both should be considered for patients whose ventricular function does not normalize 3
If subsequent pregnancy is contemplated even after recovery, particularly close monitoring and continuation of GDMT (with pregnancy-safe alternatives) is essential, as recommended by the American College of Cardiology and the American Heart Association 3, 4